נורווגיה - נורבגית - Statens legemiddelverk

sandoz a/s - cefuroksimnatrium - pulver til injeksjons-/infusjonsvæske, oppløsning - 250 mg

נורווגיה - נורבגית - Statens legemiddelverk

ratiopharm gmbh - terbinafinhydroklorid - krem - 10 mg/ g

נורווגיה - נורבגית - Statens legemiddelverk

fresenius kabi norge as - vorikonazol - pulver til infusjonsvæske, oppløsning - 200 mg

האיחוד האירופי - נורבגית - EMA (European Medicines Agency)

glaxosmithkline trading services limited - flutikason furoate, umeclidinium bromide, vilanterol trifenatate - lungesykdom, kronisk obstruktiv - legemidler for obstruktive sykdommer i luftveiene, - temybric ellipta er angitt som en vedlikeholdsbehandling hos voksne pasienter med moderat til alvorlig kronisk obstruktiv lungesykdom (kols) som ikke er tilstrekkelig behandlet med en kombinasjon av en inhalert kortikosteroid og en langtidsvirkende β2-agonist eller en kombinasjon av langtidsvirkende β2-agonist og en langtidsvirkende muskarine antagonist (for effekter på symptom kontroll og forebygging av eksaserbasjoner se punkt 5..

האיחוד האירופי - נורבגית - EMA (European Medicines Agency)

novartis europharm limited - indacaterol, glycopyrronium bromide, mometasone - astma - legemidler for obstruktive sykdommer i luftveiene, - enerzair breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long acting beta2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.

האיחוד האירופי - נורבגית - EMA (European Medicines Agency)

novartis europharm limited - glycopyrronium bromide, indacaterol (acetate), mometasone furoate - astma - legemidler for obstruktive sykdommer i luftveiene, - maintenance treatment of asthma in adults whose disease is not adequately controlled.

נורווגיה - נורבגית - Statens legemiddelverk

accord healthcare b.v. - anidulafungin - pulver til konsentrat til infusjonsvæske, oppløsning - 100 mg

נורווגיה - נורבגית - Statens legemiddelverk

sun pharmaceutical - nederland - fulvestrant - injeksjonsvæske, oppløsning i ferdigfylt sprøyte - 250 mg

נורווגיה - נורבגית - Statens legemiddelverk

bioglan ab - anidulafungin - pulver til konsentrat til infusjonsvæske, oppløsning - 100 mg

האיחוד האירופי - נורבגית - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - agenter for dermatitt, unntatt kortikosteroider - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.